)
Bavarian Nordic (BAVA) investor relations material
Bavarian Nordic Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
9M revenue was DKK 4,897m, up 2.2%; Travel Health growth offset lower Public Preparedness revenue. EBITDA was DKK 1,711m, with a 34.9% margin.
Rabies-led Travel Health growth and Public Preparedness deliveries supported results; FY2026 guidance was maintained.
Strategic priorities, investment and capital allocation are under review, with an update planned for H1 2027.
Financial highlights
Q3 revenue was DKK 1,805m, up 0.6%; 9M revenue was DKK 4,897m, up 2.2%. 9M organic growth exceeded 9% excluding discontinued partnerships and FX.
Q3 gross margin was 51.9%, versus 49.8% a year earlier; 9M gross margin was 54.0%, versus 51.9%.
Q3 EBITDA was DKK 621m, with a 34.4% margin; 9M EBITDA was DKK 1,711m, with a 34.9% margin.
9M operating cash flow was DKK 489m and free cash flow DKK 68m; period-end cash and securities totaled DKK 2,984m.
Outlook and guidance
FY2026 revenue guidance remains DKK 6,100m: DKK 3,400m Travel Health, DKK 2,500m Public Preparedness and DKK 200m other revenue; EBITDA margin guidance is 32%.
Guidance assumes R&D costs of DKK 750m, CAPEX of DKK 250m and Vimkunya revenue of DKK 200m.
Travel Health seasonality and Public Preparedness order timing may drive revenue and EBITDA variability; Travel Health Q4 margin may also reflect back-end-loaded R&D and sales and marketing investment.
DKK 2,400m of 2026 Public Preparedness orders and DKK 900m of 2027 orders were secured; medium-term base guidance remains DKK 1.5bn–DKK 2bn.
- Upgraded 2026 guidance to DKK 5.7B revenue, 30% EBITDA margin, and DKK 750M buyback announced.BAVA
Q2 2026 - Travel Health growth and BARDA orders drive upgraded 2026 outlook despite lower Q1 revenue.BAVA
Q1 2026 - 2025 revenue reached DKK 6.2 billion, led by vaccine growth and PRV sale; outlook remains strong.BAVA
Q4 2025 - 33% revenue growth, 32% EBITDA margin, and a recommended takeover offer at DKK 233 per share.BAVA
Q2 2025 - Vaccine supply, portfolio growth, and new launches drive strong outlook and global expansion.BAVA
Jefferies London Healthcare Conference 2024 - Travel Health growth and major vaccine orders drive strong results and positive outlook.BAVA
Q3 2024 - H1 revenue was DKK 2,259M, with top-end 2024 guidance and mpox capacity expansion confirmed.BAVA
Q2 2024 - Q1 2025 revenue up 62% with strong margins, new vaccine launches, and robust government demand.BAVA
Q1 2025 - 2024 saw record revenue and margins, with robust vaccine sales and a strong 2025 outlook.BAVA
Q4 2024
)
)
)
)
)
)
)
)